The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 154 participants.
Also called NCT06350487
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT06350487
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT06350487. Randomized; single masking; primary purpose treatment. Start 2024-05-01 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
- Acronym
- ENRICH-PEF
- Condition
- Heart Failure, Preserved Ejection Fraction
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct06350487- Content hash
2eebb2e79956a6f5b5a82f700119b4c63edc2ba8b036cdfeed402b158e5c6cf8